Our differential analyses highlight the utility of our identified promoter-enhancer links in elucidating regulatory mechanisms and revealed widespread chromatin accessibility and gene expression changes linked to PiD and AD pathology across major cell types. This evidence concerns the gene MTA2 and Alzheimer disease.